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Background: Currently, there is no value for the definition of abdominal obesity by measuring waist circumference
in the Sub-Saharan Africa. Several definitions of metabolic syndrome (MS) have disparities concerning use of waist
circumference, including International Diabetes Federation (IDF), American Heart Association/National Heart, Lung
and Blood Institute (AHA/NHLBI) and National Cholesterol Education Program-Adult Treatment Panel III (NCEP-ATPIII)
definitions. The aim of the study was to determine what value of waist circumference should be used and whether
to use it as obligatory criterion in the metabolic syndrome in case of peripheral arterial disease (PAD).
Methods: We conducted a case–control study in Cameroon. We included patients with diabetic foot and type 2
diabetes and excluded those with an Ankle Brachial Index (ABI) > 1.3. Cases were defined as patients with ABI ≤ 0.9
and controls with ABI > 0.9. The significant p value was < 0.05 and odds ratio (OR) with 95% confidence interval
was used to measured risk for have PAD with MS.
Results: We included 19 cases and 48 controls. The risk for having PAD with MS are for the IDF: OR = 4.7 (1.4-15.1),
p = 0.008, for the AHA / NHLBI: OR = 5.8 (1.5-22.5), p = 0.007, for the NCEP-ATPIII: OR = 1.8 (0.6-5.6), p = 0.286.
Conclusion: Abdominal obesity should be defined according to the recommendations of the IDF and AHA / NHLBI
and should not be an obligatory criterion in the definition of MS for research risk to have PAD on sub-Saharan Africa.
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Africa has diabetes prevalence which is the lowest in the
world, but with the rate of undiagnosed patients which
is highest [1], one of the important risk factors for type
2 diabetes and cardiovascular risk is metabolic syndrome
(MS) [2,3]. A disparity exists between the prevalence of
MS in the same population whether subjects with dia-
betes are included or not. This disparity is due to the ex-
istence of several definitions of various medical societies
including: the International Diabetes Federation (IDF)
[2,4], the National Cholesterol Education Program-Adult
Treatment Panel III (NCEP-ATP III) [5,6], the American
Heart Association / National Heart, Lung and Blood In-
stitute (AHA / NHLBI) [7]. The diabetic foot is found in* Correspondence: bignarimjj@yahoo.fr
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reproduction in any medium, provided the or13% patients with type 2 diabetes in Cameroon [8]. In
the same study, the prevalence of MS in the population
of colored population is 60.6% according to the IDF,
55.4% according to the NCEP-ATP III [9]. In the popula-
tion of patients with type 2 diabetes in Cameroon, the
prevalence is 71.7% according to the IDF criteria and
60.4% according to the NCEP-ATPIII [10]. In Africa
since the 2000s, the prevalence of PAD in diabetics var-
ies from 12.5% to 78.7% depending on the study [11].
The relationship between MS and atherogenic risk has
already been established by several studies [2,3,7,12]. In
the criteria of JIS, it is recommended to use IDF criteria
for waist circumference in non-European [3]. But in IDF
criteria, there is no data for Sub-Saharan African con-
cerning waist circumference [2]. With the disparity
between the various definitions and the lack of informa-
tion concerning waist circumference for sub-Saharan
Africans, the present study aim to orientate towards thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Figure 1 Place of investigation of peripheral neuropathy using
10 g monofilament.
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to use to evaluate risk for have PAD in diabetic foot.
Methods
Study design
It was a case–control study conducted in 2012. The
study was approved by the administrative authorities of
the Yaoundé Central Hospital and the National Ethics
Committee of Cameroon. Data were collected after writ-
ten consent of each patient.
Setting
The study was conducted at the National Obesity Centre
in the Yaoundé Central Hospital, Cameroon. It is a ter-
tiary health care setting.
Participants
We included in the study all patients with a diabetic foot
disease and being diabetic type 2. We excluded patients
refusing to participate in the study and patients with an
ABI > 1.3 because it was uninterpretable [13,14]. In the
case group, we included patients with PAD and in the
control group patients without PAD.
Data
Age, sex and duration of diabetes were collected. The
diagnosis of PAD was done using a handheld Doppler
and 8 MHz probe. The diagnosis of PAD was based on
an ABI ≤ 0.9. The ABI was the ratio of the highest sys-
tolic pressure of the ankles to the highest systolic pres-
sure of the arms [13]. The ABI has a level of specificity
of 88.5% and sensitivity of 70.6% in type 2 diabetes pa-
tients with diabetic foot disease [15]. The sensitivity and
specificity are good to allow the usefulness of this test. It
is non-invasive method most recommended in search of
PAD in the diabetic foot [13].
We have collected the level of Total Cholesterol (TC),
High Density Lipoprotein (HDL), Low Density Lipopro-
tein (LDL) and triglycerides (TG) when we received
firstly patients. No patient had a treatment for dyslipid-
emia in the measurement of lipid levels (at the introduc-
tion in study). The waist circumference was measured
according to WHO recommendations [12]. Peripheral
neuropathy was investigated using 10 g monofilament.
The filament was applied on sole of the foot at places as
indicated in Figure 1. The pressure was made perpen-
dicularly. The diagnosis of sensitive neuropathy was
done when two of the three regions were insensitive. We
researched impalpable pulses: anterior and dorsal pedal
pulses, and popliteal pulses.
Concerning the definitions of MS, we used three dif-
ferent definitions of the following medical societies: IDF,
AHA / NHLBI and the NCEP-ATP III. The five ele-
ments that constitute the MS are identical for thesethree definitions: central obesity, increased triglycerides
(TG) levels, the blood pressure, fasting plasma glucose
and lower high density lipoproteins (HDL). The entry
criterion for the definition of the IDF is central obesity
with two of the following four elements: TG levels ≥
1.7 mmol/L or specific treatment for abnormal levels of
TG, HDL <1.03 mmol/L in men and <1.29 mmol/L in
women or specific treatment for abnormal levels of
HDL, systolic blood pressure ≥ 130 mmHg or diastolic
blood pressure ≥ 85 mmHg or previous diagnosis of
hypertension, fasting plasma glucose ≥ 5.6 mmol/L or
prior diagnosis of type 2 diabetes [2]. For the last elem-
ent (type 2 diabetes), all patients in the study had it, it
remained to find the other four. For defining central
obesity, in the absence of specific data for sub-Saharan
African, we used data from the European population for
men and ≥ 94 cm for women ≥ 80 cm [2]. The definition
of the NCEP ATPIII-differs from the IDF on three com-
ponents: central obesity is not an obligatory criterion,
the definition of central obesity is made for a waist cir-
cumference > 102 cm in men and > 88 cm in women
without taking account of ethnic origin, increased fasting
plasma glucose is set to blood glucose levels ≥ 6.1 mmol/L
[6,16]. The definition of the AHA / NHLBI differs from
the IDF on a single element: central obesity is not an entry
criterion [3]. The most recent, the joint interim statement
definition was presented in Table 1 [3].
Statistical analysis
The sample size of each group was calculated using the
WinPepi [17]. The ratio in Sub-Saharan Africa of diabetic
Table 1 Joint interim statement definition of metabolic
syndrome [3]
Measure Categorical cut points
Elevated waist circumference* Population- and country-specific
definitions
Elevated triglycerides (drug treatment for
elevated triglycerides is an alternate
indicator)†
≥ 150 mg/dL (1.7 mmol/L)
Reduced HDL-C (drug treatment for
reduced HDL-C is an alternate
indicator)†
< 40 mg/dL (1.0 mmol/L)
in males
< 50 mg/dL (1.3 mmol/L)
in females
Elevated blood pressure (antihypertensive
drug treatment in a patient with a history
of hypertension is an alternate indicator)
Systolic≥ 130 and/or
diastolic≥ 85 mm Hg
Elevated fasting glucose‡ (drug treatment
of elevated glucose is an alternate
indicator)
≥ 100 mg/dL
HDL-C = High Density Lipoprotein.
*It is recommended that the IDF cut points be used for non-Europeans and
either the IDF or AHA/NHLBI cut points used for people of European origin
until more data are available.
†The most commonly used drugs for elevated triglycerides and reduced HDL-C
are fibrates and nicotinic acid. A patient taking 1 of these drugs can be presumed
to have high triglycerides and low HDL-C. High-dose −3 fatty acids presumes high
triglycerides.
‡Most patients with type 2 diabetes mellitus will have the metabolic syndrome
by the proposed criteria.
Table 2 General characteristics of the study population
Variables PAD (+) PAD (−) p
n = 19 n = 48
Ankle brachial index (SD) .75 (.14) 1.09 (.11) < .001
Age, years (SD) 49.3 (7.2) 50.8 (12.3) .53
Male, n (%) 11 (57.9) 19 (39.6) .17
Duration of diabetes, years (SD) 6.9 (3.1) 7.6 (4.6) .55
Waist circumference, cm (SD)
- Male 101.2 (9.7) 89.9 (7.1) .001
- Female 94.6 (5.0) 91.2 (11.6) .044
Impalpable pulses, n (%) 15 (78.9) 4 (8.3) < .001
Sensitive peripheral neuropathy, n (%) 16 (84.2) 37 (77.1) .74
Infection, n (%) 18 (94.7) 47 (97.9) .49
HbA1c, mmol/mol (SD) 92.4 (9.3) 84.7 (7.1) .39
Cholesterol, mmol/L (SD)
- Total Cholesterol 5.65 (1.63) 5.37 (1.64) .54
• Male 6.63 (1.25) 5.69 (1.50) .09
• Female 4.29 (.99) 5.17 (1.72) .18
- High Density Lipoprotein 1.07 (.42) 1.57 (.55) < .001
• Male 1.00 (.54) 1.33 (.62) .16
• Female 1.15 (.17) 1.73 (.43) .001
- Triglycerides 4.02 (1.65) 3.01 (1.71) .031
• Male 4.60 (1.36) 3.42 (1.35) .029
• Female 3.24 (1.77) 2.74 (1.88) .50
- Low Density Lipoprotein 2.35 (.30) 2.14 (.49) .033
• Male 2.32 (.38) 2.30 (.33) .87
• Female 2.40 (.14) 2.03 (.56) .032
PAD (+): diabetes patients with peripheral arterial disease.
PAD (−): diabetes patients without peripheral arterial disease.
SD, Standard deviation.
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using a Doppler [18]. We used 2.6 for the ratio between
population sizes of each group because it approaches
unity. We assume that the prevalence of metabolic syn-
drome was 30% in the population of patients without
PAD and 70% in the population with PAD. The required
size was 16 cases and 42 controls for a supposed power of
80% and p-value of 0.05. Data was coded, entered, and an-
alyzed using the Statistical Package for Social Science
(SPSS) version 19 for Windows (SPSS, Chicago, Illinois,
USA). Continue variables were expressed as mean (standard
deviation) and compared using t-test of Student. Categorical
variables were expressed as frequencies (percentages) and
compared using the two-tailed Chi-square test or its equiva-
lents. A p-value less than 0.05 was considered statistically
significant. Elements of MS were included in the univariate
analysis as factors of PAD. All elements of the MS were then
incorporated into a multivariate logistic analysis even with-
out significance in the univariate analysis. Two logistic ana-
lyzes were conducted: one with central obesity according to
the recommendations of the IDF and AHA / NHLBI and
other elements of MS, and the other with android obesity as




We included 19 subjects in the group of patients with PAD
and 48 without PAD. A statistically significant differencewas found between patients with and without PAD con-
cerning waist circumference in men and women, HDL and
LDL levels in all subjects and among women, TG level in all
subjects and among men, and pulse abnormality (Table 2).
Components of metabolic syndrome
Table 3 presents the analysis of components of meta-
bolic syndrome as a risk factor for PAD in the diabetic
foot. In the univariate analysis, PAD of diabetic foot is
significantly associated to the definition of the waist of
the IDF and AHA / NHLBI than that of the NCEP-ATP
III. No other element of MS is significantly related to
PAD. Table 3 presents the multivariate analysis of the el-
ements of MS according to the two definitions of ab-
dominal obesity. In multivariate analysis of the elements
of MS of IDF and AHA / NHLBI definitions, those sig-
nificantly associated with PAD are abdominal obesity
and abnormal levels of HDL. The same elements were
found in the definition of the NCEP- ATPIII.
Table 3 Analysis of MS and its components as risk factors of PAD of diabetic foot
PAD (+) PAD (−) p Crude OR
n = 19 n = 48 (95% CI)
Elements of Metabolic Syndrome, n (%)
Abnormal waist circumference* 16 (84.2) 18 (37.5) .001 8.9 (2.3; 34.8)
Abnormal waist circumference§ 11 (57.9) 16 (33.3) .06 2.8 (0.9; 8.2)
High density lipoprotein-Cholesterol male < 1.03 or female < 1.29 mmol/L 10 (52.6) 13 (27.1) .047 3.0 (1.0; 9.0)
Triglycerides ≥ 1.7 mmol/L 9 (47.4) 16 (33.3) .25 1.8 (0.6; 5.3)
Blood pressure ≥130/85 mmHg or Hypertension on treatment 10 (52.6) 25 (52.1) .97 1.0 (0.4; 3.0)
Metabolic Syndrome n, (%)
IDF criteria 14 (73.7) 18 (37.5) .008 4.7 (1.4; 15.1)
NCEP-ATPIII criteria 13 (68.4) 26 (54.2) .29 1.8 (0.6; 5.6)
AHA/NHLBI criteria 16 (84.2) 23 (47.9) .007 5.8 (1.5; 22.5)
*≥ 94 cm in men, ≥ 80 cm.
§≥ 102 cm in men, ≥ 88 cm in women.
PAD (+): patients with peripheral arterial disease.
PAD (−): patients without peripheral arterial disease.
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Table 4 presents the analysis of different definitions of
the metabolic syndrome as a risk factor in PAD of dia-
betic foot. We had a significant association of definitions
of the IDF and AHA / NHLBI with a better association
with the criteria of the AHA / NHLBI.
Discussion
In this study, we found that better correlation of PAD of
diabetic foot disease was with the definition of AHA /
NHLBI. Limitation of study was due to that patients
with arterial hypertension were in treatment. This is a
cross-sectional study and we not able to measure the
direct effect of risks factors.
No studies found in the literature have been per-
formed in the patient population with a diabetic foot.
Several studies found an association of PAD with MS ac-
cording to the WHO criteria [19,20] unlike the study by
Wong et al. [21]. Concerning the association of PAD
with MS according to NCEP-ATPIII, several studies




Abnormal waist circumference* .002 1
Abnormal waist circumference§ -
High density lipoprotein-Cholesterol
male < 1.03 or female < 1.29 mmol/L
.013
Triglycerides ≥ 1.7 mmol/L .58
Blood pressure ≥130/85 mmHg or
Hypertension on treatment
.99
*≥ 94 cm in men, ≥ 80 cm.
§≥ 102 cm in men, ≥ 88 cm in women.study by Larsson et al. goes in the direction of ours, es-
pecially since it is cohort study [19]. The risk of having
PAD in another study was higher with the five elements
of the MS combined [22], a study in Spain showed a 14
times higher risk of having a PAD in the presence of MS
[23]. On the criteria of the AHA / NHLBI, one study
found no association with PAD [25]. The difference with
our study is that the analysis is done with a logistic re-
gression in combination of other factors. On the IDF cri-
teria, a study found no relationship with PAD in a
population of patients aged 50 to 75 years, without spe-
cification of diabetes status [22]. The same results were
found in a population of Indian patients [24]. A study
showed a better association for IDF criteria than for the
AHA / NHLBI criteria, in contrast to our study [26].
The association between MS and PAD in the diabetic
foot is more significant for the definition of AHA /
NHLBI than that of the IDF in our study. No association
was found with the definition of the NCEP-ATPIII.
Thus, in our study, the risk is higher using the definition
of the AHA / NHLBI. The difference between thebolic syndrome according to different definitions
defined as IDF
LI*
With waist circumference defined as
NCEP-ATP III§
djusted OR p Adjusted OR
3.8 (2.6; 73.8) - -
- .020 5.3 (1.3; 21.7)
6.5 (1.5; 28.2) .006 8.2 (1.8; 36.8)
1.5 (0.4; 6.5) .15 2.6 (0.7; 10.0)
1.0 (0.2; 4.1) .38 1.8 (0.5; 6.4)
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uated at the android obesity. Waist circumference to
consider is ≥ 94 cm in men and ≥ 88 cm in women for
the diagnosis of abdominal obesity in sub-Saharan Afri-
cans. The difference between the criteria of AHA /
NHLBI and the IDF is at the level of abdominal obesity
which is an obligatory criterion for the IDF. With a
higher risk with the criteria of the AHA / NHLBI com-
pared to the IDF (5.8 against 4.7), so it is important not
to consider abdominal obesity as obligatory criteria for
assessing the risk of developing PAD in the presence of
MS like JIS definition [3].
Regarding the elements of MS, in univariate analysis
in our study, the definition of abdominal obesity accord-
ing to IDF and AHA / NHLBI is associated with PAD in
diabetic foot contrary to the definition of the NCEP-
ATPIII. In addition, in the multivariate analysis with
other elements of the MS, the two definitions of abdom-
inal obesity are associated with MS. The correlation is
still higher than with the IDF and AHA / NHLBI. It
spends 13.8 with the definition of IDF and AHA /
NHLBI to 5.3 with that of the NCEP-ATPIII. This fur-
ther demonstrates that the definition of abdominal obes-
ity adopted in the diabetic population of sub-Saharan
Africa as a risk factor for PAD in the diabetic foot
should be that of the IDF and AHA / NHLBI and not
that of the NCEP-ATPIII. The fact that it is only in the
presence of other elements of the MS that abdominal
obesity as defined by the NCEP-ATPIII become a risk
factor for further demonstrates the weakness of the limit
imposed for the significance of waist circumference in
the definition of abdominal obesity. The risk of having
PAD in the diabetic foot when the patient has abdominal
obesity according to the criteria of the IDF and AHA /
NHLBI increases in the presence of other elements of
the MS as it goes from 8.9 to 13.8. This means that the
association of this definition of abdominal obesity with
other elements of MS, especially an abnormal rate of
HDL increases the risk of having PAD. The abnormal
level of HDL is the second factor involved in PAD dia-
betic foot after abdominal obesity. The risk rose from
3.0 in the univariate analysis at 6.5 with the criteria of
the IDF and AHA / NHLBI to 8.5 with the criteria of
NCEP-ATPIII in the multivariate analysis. Be it single or
in the presence of other components of MS, an abnor-
mal HDL fact evokes the presence of PAD in diabetic
foot in sub-Saharan Africa but with a higher risk in the
presence of other components of MS. The presence of
the other two elements of MS, hypertension and abnor-
mal levels of TG, do not imply the presence of PAD in
the diabetic foot in our study, both in univariate or
multivariate analysis. Relying on these data, it is only by
integrating them into the diagnostic criteria for MS that
they are considered.Our study has some limitations that are important to
report. It was a case–control study; the direct risk has
not been evaluated. In addition, the study was conducted
in a reference center that is a tertiary institution.
Reflected in the structure of primary health care cannot
be assessed, but the results can be compared to those
made in other countries of sub-Saharan Africa, given the
similarity of the study sites.
Conclusion
The definition of MS which better evaluates the risk to
have a PAD in diabetic foot is the AHA / NHLBI defin-
ition. Thus, abdominal obesity should be defined accord-
ing to the recommendations of the IDF and AHA /
NHLBI and should not be an obligatory criterion in the
definition of MS for research risk to have PAD in dia-
betic foot disease on sub-Saharan Africa.
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